132671Novel chemical libraries to unlock the potential of deubiquitylase enzyme drug discoveryClosedFeasibility StudiesInnovate UKDespite advancements in the pharmaceutical industry there remains a significant need for new therapies to address unmet clinical needs. The ubiquitin system defines a cascade of proteins that control regulated protein turnover amongst other functions. Its key role in the regulation of probably the majority if not all cellular proteins and processes means that it presents a deep array of potential drug targets - currently largely untapped by the pharma industry - addressing multiple therapeutic areas including many currently proving challenging such as dementia, cancer and metabolic diseases. Ubiquigent is a world leading provider of biological assay services in this newly emerging ubiquitin system drug discovery space. The main rate limiting factor in ubiquitin system targeted drug discovery is the availability of small molecule chemistry that may provide the starting points for developing drugs against this family of targets. With the help of this grant Ubiquigent will develop first in class ubiquitin system (focussing on the deubiquitylase enzyme sub family) targeted small molecule libraries to unlock ubiquitin system drug discovery across the pharmaceutical industry to enable the development of critical future medicines.